co-enzyme A) reductase. Other means of lowering LDL cholesterol such as bile acid sequestrants and partial ileal bypass (which reduce absorption of bile acids) and ezetimibe (which blocks cholesterol absorption) up-regulate the HMG-CoA reductase pathway and hence cannot exert the pleiotropic effects attributed to statins. A recent meta-analysis 2
investigated this issue and concluded that the reduction in coronary events seen in statin and non-statin trials did not differ and were consistent with a one-to-one relationship between LDL cholesterol lowering and coronary heart disease reduction. Thus, the effects of statins in reducing coronary events are explicable entirely on the basis of their cholesterol-lowering properties.
The ENHANCE (Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression) trial 3 examined the effects on carotid intima-media thickness (IMT) of simvastatin alone versus simvastatin plus ezetimibe in patients with familial hypercholesterolaemia and found no difference between the treatment groups after 2 years. However, the design of the study was flawed inasmuch as the IMT was normal in both groups at baseline, reflecting years of previous statin therapy, and it remained so throughout the trial. The latter was not powered to examine the effect of ezetimibe on clinical events, but this is being tested in IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial), 4 which has so far recruited 13 500 of a planned 18 000 post-acute coronary syndrome patients. 5 These are randomized to receive simvastatin alone or together with ezetimibe for a minimum of 2.5 years or until 5250 patients experience a cardiovascular event. Until the outcome of that trial is known, ezetimibe remains an effective adjunct to statin therapy in high-risk patients, especially those with a substandard response to statin monotherapy. 6 I suggest to Dr Grimes that this strategy reflects an evidence-based rather than an evangelical approach to resolving this latest chapter of the cholesterol controversy. Variability in the prevalence of radiographic stigmata and in their use for profiling disease severity makes comparisons more complicated
Sir, The fact that as many as 21% of the patients with a clinical diagnosis of community-acquired pneumonia (CAP) may have 'negative' chest radiographs on admission 1 adds complexity to the validation of CAP by chest radiography, 2 and also has the potential to complicate comparisons of profiles of disease severity, 3 given the fact that, in some profiles, radiographic stigmata make a contribution to the eventual severity score, 4 and in others they do not. 4 Although the 'reference standard to diagnose CAP is a new infiltrate on chest radiograph in the presence of recently acquired respiratory signs and symptoms', 2 patients who have negative chest radiographs on admission have clinical stigmata and disease severity comparable withtheir counterparts with positive chest radiographs. 1 To complicate matters even further, although only a minority of chest radiograph-negative patients with clinical stigmata of CAP have been followed up with repeat imaging studies, in 44% of those instances of repeat imaging, an infiltrate was identified, which was not present in the initial chest radiograph. 1 In terms of prognostic implications, useful analogies can be derived from similarities between chest radiograph-negative patients with clinical stigmata of CAP, and patients with 'masked' hypertension, the latter characterized by normal 'office' blood pressure in spite of 'out-of office' measurements in the hypertensive range. 5 The starting point is that the prevalence of 'negative' chest radiography in patients who have clinical stigmata of CAP is virtually identical with the upper limit (i.e. 20.5%) of the prevalence of masked hypertension in the hypertensive population. 5 The corollary is that the presence of comparable disease severity in chest radiographnegative and in their chest radiograph-positive counterparts resonates with the documentation that individuals with masked hypertension have 'similar cardiovascular risk as sustained hypertensives but they remain undetected'. 5 Accordingly, just as risk profiling of all hypertensive patients will only come of age when detection of this disorder also encompasses detection of masked hypertension, optimum severity assessment for CAP will only be achieved when due account is also taken of chest radiograph-negative subjects with clinical stigmata of this disorder. Meantime, where the index of suspicion for CAP is sufficiently high modalities such as computed tomography might have to be utilized to validate the diagnosis in the event of the occurrence of 'negative' plain chest radiographs. 
